MaxCyte and Ori Biotech Partner to Enhance CAR-T Cell Manufacturing Through Platform Integration
核心洞察
MaxCyte (搜索) and Ori Biotech (搜索) announced a strategic collaboration integrating their ExPERT™ and IRO® platforms to improve gene-edited T cell yields and reduce manufacturing timelines.
The partnership will evaluate CD19 (搜索) CAR expression via CRISPR (搜索) knock-in in activated T cells as the initial test system to optimize manufacturing processes.
MaxCyte (搜索)'s Flow Electroporation® technology, used in over 19 active clinical and commercial programs, will be combined with Ori's automated manufacturing platform.
MaxCyte (搜索), Inc. and Ori Biotech (搜索) Ltd. announced a strategic collaboration on June 11, 2025, aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing through the integration of their respective platform technologies.
Platform Integration Strategy
The collaboration combines MaxCyte (搜索)'s ExPERT™ platform and Flow Electroporation® technology with Ori's next-generation cell therapy manufacturing platform, IRO® (ee-RO). MaxCyte's technology is widely recognized for its efficient and scalable transfection capabilities and is currently utilized in over 19 active clinical and commercial programs.
The partnership will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte (搜索)-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, the companies have selected CD19 (搜索) CAR expression via CRISPR (搜索) knock-in in activated T cells as the test system for initial evaluation.
Technology Synergies
MaxCyte (搜索)'s technology offers flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability.
Together, these complementary technologies provide therapy developers with a toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently.
Leadership Perspectives
Maher Masoud, President and CEO of MaxCyte (搜索), commented, "We are excited to collaborate with the team at Ori Biotech (搜索), combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients."
Jason C. Foster, CEO of Ori Biotech (搜索), stated, "Our partnership with MaxCyte (搜索) is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing. By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale."
Manufacturing Innovation Impact
The collaboration represents an effort to enable developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally.
MaxCyte (搜索) has been advancing cell engineering for more than 25 years, providing Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services. Ori Biotech (搜索)'s IRO® platform automates cell therapy manufacturing with the goal of increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics.